Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

  title={Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.},
  author={Allison W. Kurian and Kevin C Ward and Nadia Howlader and Dennis Deapen and Ann S. Hamilton and Angela B. Mariotto and Daniel G. Miller and Lynne Penberthy and Steven J. Katz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={37 15},
  • A. KurianK. Ward S. Katz
  • Published 9 April 2019
  • Medicine, Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Genetic testing for cancer risk has expanded rapidly. We examined clinical genetic testing and results among population-based patients with breast and ovarian cancer. METHODS The study included all women 20 years of age or older diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014 and reported to the SEER registries covering the entire state populations. SEER data were linked to results from four laboratories that performed nearly all germline cancer… 

Figures and Tables from this paper

Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.

Among breast cancer and ovarian cancer patients treated with chemotherapy in the community, BRCA1/2 and other gene PV carriers had equivalent or lower short-term cancer-specific mortality than non-carriers.

Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.

  • A. KurianK. Ward S. Katz
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2021
A testing gap persists for patients with ovarian cancer, whereas adding more genes widened a racial or ethnic gap in VUS results, measuring testing trends, rates of variants of uncertain significance (VUS), and pathogenic variants (PVs).

Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.

Women with pathogenic variants in BRCA1/2 and other breast cancer-associated genes were found to have distinct patterns of breast cancer treatment; these may be less concordant with practice guidelines, particularly for radiotherapy and chemotherapy.

Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system

Examination of clinical, demographic, and socioeconomic factors from electronic health records associated with genetic referral and testing within 12 months after a new cancer diagnosed between August 1, 2013 and December 31, 2018 found race was a significant factor only for breast cancer, with fewer Asians than Whites referred.

Multigene assessment of genetic risk for women for two or more breast cancers

It is demonstrated that several high and moderate penetrance breast cancer susceptibility genes are associated with two or more breast cancers, affirming the association of two ormore breast cancers with diverse genetic etiologies.

Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer

Despite increased testing over time, many patients did not receive testing, suggesting missed opportunities to identify patients appropriate for targeted therapy and genetic counseling.

Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer

Recommendations for survivorship care that incorporate ongoing genetic risk assessment and counseling for breast cancer patients are supported, suggesting under-diagnosis of PC risk.

Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.

Mutation rates are at least 7% in all patients with BRCA1/2 mutation-negative MP-BC, regardless of age at diagnosis of breast cancer, with mutation rates up to 25% in patients with a first breast cancer diagnosed at age < 30 years.

Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes

PVs in BRCA1, but not BRCa2, PALB2, ATM, CHEK2, or Lynch syndrome genes, were associated with elevated RS on multivariable analysis (P < .001), which may inform RS testing decisions in breast cancer patients with PVs.

Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment

BRCA1/2 PV carriers with HR-positive, HER2-negative breast cancer had twofold higher odds than noncarriers of receiving a platinum, as part of a more intensive chemotherapy regimen, and emphasizes the need to monitor how genetic testing results are managed in oncology practice.



Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

Nearly half of patients with breast cancer with a P/LP variant with clinically actionable and/or management guidelines in development are missed by current testing guidelines, suggesting that all patients with a diagnosis of breast cancer undergo expanded panel testing.

Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.

  • A. KurianYun Li S. Katz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
Many patients with breast cancer are tested without ever seeing a genetic counselor, suggesting a limited understanding of results that some surgeons share, and the need to address challenges in personalized communication about genetic testing.

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

  • N. TungN. Lin J. Garber
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
Factors that predict for BRCA1/2 mutations do not predict for mutations in other breast/ovarian cancer susceptibility genes when these genes are analyzed as a single group.

Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.

  • S. KatzK. Ward A. Kurian
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
There is a large gap between mandates for timely pretest formal genetic counseling in higher-risk patients and the reality of practice today.

Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer

Multiple-gene sequencing rapidly replaced BRCA1/2-only testing for patients with breast cancer in the community and enabled 2-fold higher detection of clinically relevant pathogenic variants without an associated increase in prophylactic mastectomy.

Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer

In this study, the attending surgeon was associated with the receipt of genetic testing after a breast cancer diagnosis and variation in surgeon attitudes about genetic testing and counseling may explain a substantial amount of this association.

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

Several panel genes are established as high- and moderate-risk breast cancer genes and estimates of breast cancer risk associated with pathogenic variants in these genes among individuals qualifying for clinical genetic testing are provided.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone.

Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

Among BRCA1 mutation carriers, as among noncarriers, there are unique characteristics associated with the triple-negative subtype, and Ashkenazi Jewish women were about five times more likely to have TNBC than non-AshkenaziJewish women.

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing

Multigene hereditary cancer panel testing can identify women with elevated risk of TNBC due to mutations in BARD1, BRCA1,BRCA2, PALB2, and RAD51D, and these women can potentially benefit from improved screening, risk management, and cancer prevention strategies.